Antibodies against N-Methyl D-Aspartate Receptor in Psychotic Disorders: A Systematic Review.

IF 2.3 4区心理学 Q3 NEUROSCIENCES

Neuropsychobiology Pub Date : 2022-01-01 Epub Date: 2021-05-17 DOI:10.1159/000515930

Alexey A Murashko, Konstantin A Pavlov, Olga V Pavlova, Olga I Gurina, Alexander Shmukler

{"title":"Antibodies against N-Methyl D-Aspartate Receptor in Psychotic Disorders: A Systematic Review.","authors":"Alexey A Murashko, Konstantin A Pavlov, Olga V Pavlova, Olga I Gurina, Alexander Shmukler","doi":"10.1159/000515930","DOIUrl":null,"url":null,"abstract":"Objective: The objective of this study was to provide comprehensive evidence synthesis including all available up-to-date data about the prevalence of N-methyl D-aspartate receptor (NMDAR) antibodies (ABs) in psychotic patients in order to evaluate the clinical relevance of ABs as well as to specify potential explanations of the heterogeneity of the findings and determine areas for further research.Methods: A literature search was conducted using the PubMed/Medline, Web of Knowledge, and Scopus databases.Results: Forty-seven studies and 4 systematic reviews (including 2 meta-analyses) were included in the present review. Studies that used cell-based assays (CBAs) provided heterogeneous results on AB prevalence, obviously depending on the type of detection assay and sample characteristics. Improvement of AB detection methods is necessary to determine the real prevalence of ABs across different groups of patients and healthy people. Live CBAs seem to have better sensitivity but probably poorer specificity than fixed CBAs. Moreover, some links between AB-positive status and acute symptoms are possible. A small amount of data on immunotherapy in AB-positive patients raises the possibility of its effectiveness but obviously require further research.Conclusions: NMDAR ABs are definitely present in a subset of psychotic patients. NMDAR ABs might shape psychosis and underlie some symptoms, and immunotherapy might be regarded as a treatment option for patients failing to respond to other therapies.","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000515930","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropsychobiology","FirstCategoryId":"102","ListUrlMain":"https://doi.org/10.1159/000515930","RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/5/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 5

Abstract

Objective: The objective of this study was to provide comprehensive evidence synthesis including all available up-to-date data about the prevalence of N-methyl D-aspartate receptor (NMDAR) antibodies (ABs) in psychotic patients in order to evaluate the clinical relevance of ABs as well as to specify potential explanations of the heterogeneity of the findings and determine areas for further research.

Methods: A literature search was conducted using the PubMed/Medline, Web of Knowledge, and Scopus databases.

Results: Forty-seven studies and 4 systematic reviews (including 2 meta-analyses) were included in the present review. Studies that used cell-based assays (CBAs) provided heterogeneous results on AB prevalence, obviously depending on the type of detection assay and sample characteristics. Improvement of AB detection methods is necessary to determine the real prevalence of ABs across different groups of patients and healthy people. Live CBAs seem to have better sensitivity but probably poorer specificity than fixed CBAs. Moreover, some links between AB-positive status and acute symptoms are possible. A small amount of data on immunotherapy in AB-positive patients raises the possibility of its effectiveness but obviously require further research.

Conclusions: NMDAR ABs are definitely present in a subset of psychotic patients. NMDAR ABs might shape psychosis and underlie some symptoms, and immunotherapy might be regarded as a treatment option for patients failing to respond to other therapies.

查看原文本刊更多论文

抗n -甲基d -天冬氨酸受体在精神疾病中的抗体:系统综述。

目的:本研究的目的是提供全面的证据合成，包括所有可获得的关于精神病患者n -甲基d -天冬氨酸受体(NMDAR)抗体(ABs)患病率的最新数据，以评估ABs的临床相关性，并指定结果异质性的潜在解释，并确定进一步研究的领域。方法:使用PubMed/Medline、Web of Knowledge和Scopus数据库进行文献检索。结果:本综述纳入了47项研究和4项系统评价(包括2项荟萃分析)。使用基于细胞的测定法(cba)的研究提供了不同的AB患病率结果，这显然取决于检测方法的类型和样品特征。需要改进抗体检测方法，以确定不同患者群体和健康人之间抗体的真实患病率。活体cba似乎比固定cba具有更好的敏感性，但可能较差的特异性。此外，在ab阳性状态和急性症状之间可能存在一些联系。免疫治疗在ab阳性患者中的少量数据提高了其有效性的可能性，但显然需要进一步的研究。结论:NMDAR抗体确实存在于一部分精神病患者中。NMDAR抗体可能形成精神病并成为某些症状的基础，免疫疗法可能被视为对其他疗法无效的患者的一种治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuropsychobiology 医学-精神病学

CiteScore

7.20

自引率

0.00%

发文量

审稿时长

6 months

期刊介绍： The biological approach to mental disorders continues to yield innovative findings of clinical importance, particularly if methodologies are combined. This journal collects high quality empirical studies from various experimental and clinical approaches in the fields of Biological Psychiatry, Biological Psychology and Neuropsychology. It features original, clinical and basic research in the fields of neurophysiology and functional imaging, neuropharmacology and neurochemistry, neuroendocrinology and neuroimmunology, genetics and their relationships with normal psychology and psychopathology. In addition, the reader will find studies on animal models of mental disorders and therapeutic interventions, and pharmacoelectroencephalographic studies. Regular reviews report new methodologic approaches, and selected case reports provide hints for future research. ''Neuropsychobiology'' is a complete record of strategies and methodologies employed to study the biological basis of mental functions including their interactions with psychological and social factors.